Inflammation Research 2004: Vol 53 Index

2004·1.7 MB·English

Inflammation
Research
Author Index
Aarbiou, J., 230 D'Ambrosio, A. L., 497 Hajos, S. E., 556 Kuroda, M., 462
Ackermann, M., 13, 107 Davis, S. V., 390 Hamanishi, C., 239, 344 Kurtel, H., 329
Acsady, G., 631 Dawson, J., 133 Harada, H., 45
Adachi, M., 277 De Backer, W. A., 143 Harvey, R., 53, 60 bai. $422
Aihara, N., 199 de Boer, W. I., 230 Hayes, J. R., 390 Landgraf, R. G., 657
Alaniz, L., 556 deMello, D. E., 475 Haynes, D. R., 596 Lang, S., 528
Alba-Loureiro, T. C., 657 Deniz, M., 329 Heaney, L. G., 171 Laskay, T., 38
Alberty, J., 111 DiMattia, D. A., 377 Helin, H., 489 Lendemans, S., 13
Alique, M., 297 Dosa, E., 631 Henderson Jr., J. D., 22 Lentsch, A. B., 257
Alvarez, E., 556 Drummond, P. D., 309 Henzgen, S., 189 Leung, P. C., 663
Andrade, S. P., 576 Dullea, R. G., 377 Hernandez-Vidal, G., 107 Li, W. Y., 304
Antoine, M., 4 Dvortsak, E., 528 Herrero, J. F., 297 Liang, L., 363
Arechavaleta- Velasco, F., 567 Dziurdzik, P., 338 Hiemstra, P. S., 230 Liggins, R. T., 363
Artym, J., 292 Hiraishi, K., 277 Lipnik-_tangelj, M., 245
Asada, S., 344 Eichelbronner, O., 158 Hirata, M., 609 Liu, J., 484, 663
Ashwood, P., 53, 60 Elbers, A., 223 Hoebe, K. H., 93 Livingston, M., 171
Endresz, V., 413 Hoffmann, J. W., 475, 528 Lobo de Araujo, A., 284
Baar, V., 688 Ennis, M., 171, 181, 211 Holthaus, R., 257 Lofberg, R., 1
Bacon, K. B., 489 Entz, L., 631 Homandberg, G. A., 396, Lopes, L. R., 657
Bajor, T., 262 Esser, R., 133 405, 534 Lopez-Bojorquez, L. N., 567
Bakker, R. A., 509 Horiuchi, Y., 217 Lorenz, W., 696
Barcelos, L. S., 576 Faber, C., 688 Hrabak, A., 262 Lucio, F. J., 297
Bauhofer, A., 696 Faccioli, L. H., 351 Hua, J., 679 Luyten, C., 143
Bellocgq, A., 4 Fairweather, I., 118 Hunter, W. L., 363 Ly, R., 304
Belon, P., 181 Falus, A., 38, 179, 517 Husain, B., 13
Bene, L., 551 Farberman, M. M., 475 Huszti, Z., 551 Magari, K., 469, 544
Berliner, S., 458 Farkas, A., 262 Malheiro, A., 351
Bisignano, G., 601 Farsky, S. H., 442 Ichikawa, H., 462 Manabe, H., 31
Blanco, G., 556 Fekete, B., 551 Ichiyama, T., 253 Mannaioni, P. F., 181
Bon, C., 284 Ferreira de Araujo, P. M., 284 Isumi, H., 253 Mano, Y., 217
Borelli, P., 442 Ferreira Jr, J. M., 442 Iwabuchi, K., 679 Martins, E. F., 657
Borggrefe, M., 528 Flohé, S., 13 Izeboud, C. A., 93 Matsubara, T., 253
Brauer, R., 189 Fock, R. A., 442 Matsukawa, M., 239
Briuglia, S., 601 Forman, M. F., 453 Jackson, J. K., 355 Matsushita, T., 344
Brower, G. L., 453 Frangogiannis, N. G., 585 Jaggi, R., 150 Mauad, T., 230
Brueckmann, M., 528 Fukuda, K., 239, 344 Jalowiecki, P., 338 Mayaud, C., 4
Bryda, E. C., 390 Fiilop, A. K., 517 Jancar, S., 78, 657 McGlone, F., 118
Burian, K., 413 Furukawa, S., 253 Janicki, J. S., 453 Medeiros, A. I., 351
Burt, H. M., 355, 363 Fiist, G., 551, 631 Jelinek, I., 413 Mehra, A., 497
Busch, C. J., 205 Jochem, J., 269, 316 Mello, S. B., 442
Buzas, E., 38 Gabra, B. H., 652 Jose, P. J., 351 Menger, M. D., 205, 523
Gabriel, A., 66 Menon, L., 338
Cabrera, P. V., 556 Gama Landgraf, R., 78 Kaden, J. J., 528 Merlino, M. V., 601
Cadranel, J., 4 Gangemi, S., 601 Kanekawa, M., 199 Milleron, B., 4
Carman-Kr_an, M., 245 Garcia, M., 556 Kang, H., 396, 534 Min, W., 363
Cashman, J., 355 Gawlicka, M., 100 Karadi, I., 631 Minciullo, P. L., 601
Cassali, G. D., 576 Germonpré, P., 143 Kasai, K., 199 Misawa, M., 636
Cetinel, S., 329 Giannoulaki, V., 373 Katada, K., 462 Mitchell, J., 66
Chen, G. G., 663, 484, 669 Girschick, H. J., 688 Kato, A., 257 Miyasaka, C. K., 657
Chiba, Y., 636 Gleave, J., 355 Katsumata, T., 45 Miyata, S., 469, 544
Chodaczek, G., 292 Gonczol, E., 413 Kis, Z., 413 Molina, C., 297
Cimino, F.,, 601 Grandjean, F., 150 Kocieba, M., 292 Montes-Sanchez, D., 567
Connolly, E. S., 497 Greczanik, S., 556 Kojima, T., 199 Morbach, H., 688
Conroy, D. M., 351 Green, T. L., 390 Kokura, S., 462 Moreau, J., 4
Cruz, T., 363 Grootendorst, A. F., 93 Kondera-Anasz, Z., 338 Moreno-Manzano, V., 297
Cruz-H6fling, M. A., 284 Grosios, K., 133 Kondo, S., 489 Mori, S., 164
Cumps, J., 181 Gruetter, C. A., 215, 390 Koster, M., 696 Morita, I., 217
Curi, R., 657 Guimaraes, A. Q., 284 Kovacs, A., 551 Moriyama, K., 66
Gutiérrez-Ornelas, E., 107 Krawczyk, L., 338 Miiller, K., 38
Dallapiccola, B., 601 Haase, K. K., 528 Kruzel, M. L., 292 Munakata, H., 344, 239
Muneta, T., 217 Romero-Sandoval, E. A., 297 Tamura, H., 609 Yomogida, S., 609
Murata, H., 72 Romics, L., 551, 631 Tan, Z. R., 484 Yoshida, K., 344, 239, 462
Muroi, N., 164 ROntzsch, A., 189 Tanaka, T., 45 Yoshikawa, T., 462
Murthy, K. G., 604 Roza, A. M., 22 Tang, Z., 424
Mutoh, S., 469, 544 Rudack, C., 111 Teixeira, A. S., 576 Zembala, M., 100
Mytar, B., 100 Ruggiero, I., 100 Thompson, R. P., 53, 60 Zentella-Dehesa, A., 567
Rugonfalvi-Kiss, S., 631 Thompson-Cree, M. E., 211 Zhang, X. M., 669
Nagaoka, I., 609, 679 Rukwied, R., 118 Thorlacius, H., 1, 523, 643 Zhao, Y., 663
Naito, Y., 462 Ryerse, J. S., 475 Thoss, K., 189 Zhou, G., 484, 304
Nakahama, K., 217 Tiligada, E., 373 Zhu, B., 484, 22
Nakane, H., 87, 324 Sachse, F., 111 Tippens, A. S., 215, 390 Zimecki, M., 292
Nakano, K., 87, 324 Sadowska, A. M., 143 Tokita, K., 623
Nakayama, T., 45 Safronova, O., 170 Tomaino, A., 601
Nanki, T., 688 Saija, A., 601 Torkvist, L., 1
Naoe, S., 72 Sainte-Laudy, J., 181 Tsutsumi-Ishii, Y., 679
Neugebauer, E. A., 223 Sakai, H., 636
Nie, W. P., 484 Sakamoto, K., 679 Ueno, A., 636, 253
Nielsen, O. H., 458 Salpietro, D. C., 601 Umeda, Y., 623
Niimi, A., 253 Saltzman, A., 424 Ummadi, V., 396, 534
Nijmeijer, S. M., 93 Salzman, A. L., 604
Nishibori, M., 164 Saniabadi, A. R., 277 Vadillo-Ortega, F., 567
Nishigaki, F., 544 Sannomyia, P., 657 Vainer, B., 458
Nishino, N., 623 Sasaki, K., 31 Valyi-Nagy, I., 413
Nogimura, A., 199 Schade, F. U., 13 Vamos, R., 262
Novak, I., 38 Schaefer, U., 223 van Hasselt, C. A., 663
Schaefers, H. -., 523 van Krieken, J. H., 230
Oharaseki, T., 72 Schmitt, A., 696 van Miert, A. S., 93
Ohkubo, Y., 469, 544 Schmitt-Talbot, E., 377 van Overveld, F. J., 143
Okanoue, T., 462 Schneider, A., 223 van Schadewijk, A., 230
Okaya, T., 257 Schramm, R., 523, 643 Veljaca, M., 85
Ono, S., 164 Schwarting, R. K., 696 Ventura-Gallegos, J. L., 567
Onodera, M., 217 Selmeci, L., 631 Verjee, T., 53, 60
Semba, U., 623 Volimar, B., 205
Pallinger, E., 413 Sharma, M., 66
Papathanassiou, M., 373 Shi, J., 377 Wakayama, M., 72
Parente, L., 125 Shibuya, Y., 623 Wang, W., 484, 66
Parnham, M. J., 337 Shichijo, M., 489 Wanner, G. A., 205
Pawlak, C. R., 696 Shields, M. D., 211 Watanabe, T., 87, 324
Petrow, P. K., 189 Shiobara, N., 277 Weiser, M., 150
Philippe, C., 4 Singh, M., 551, 688 Wendel, A., 13
Pichika, R., 405 Sirois, P., 78, 652 Wiegant, F. A., 181
Piekarska, B., 100 Solbach, W., 38 Williams, T. J., 351
Pieper, G. M., 22 Soler, V., 4 Wislez, M., 4
Pierce Palmer, P., 66 Solito, E., 125 Witkamp, R. F., 93
Pos, Z., 38 Sonobe, Y., 87, 324 Woloszyn, M., 100
Powell, J. J., 53, 60 Sont, J. K., 230 Wolstencroft, R., 53, 60
Prohaszka, Z., 551, 631 Springate, C., 355 Wong, Y. O., 663
Proto, S. Z., 442 Steil, A. A., 78 Wong-Gonzalez, A., 107
Stevenson, M. R., 211 Woo, J. K., 663
Rabbe, N., 4 Stolk, J., 230 Wood, J., 133
Rabe, K. F., 230 Sughrue, M. E., 497 Wunder, C., 158
Ramirez-Hernandez, C., 107 Suguro, S., 679 Wiirgler, U., 150
Ramirez-Romero, R., 107 Sun, J., 304
Raud, J., 1 Szabo, A., 262, 631, 604 Xu, J. G., 304, 669, 484
Raychaudhuri, A., 133 Szatanek, R., 100
Reilly, N., 118 Yamaguchi, M., 199
Riess, P., 223 Takagi, T., 462 Yamamoto, N., 344, 623
Roberfroid, M., 181 Takahashi, H. K., 164, 72 Yamasaki, K., 239
Rodenburg, R. J., 93 Takeda, Y., 277 Yamazaki, K., 344
Roewer, N., 158 Talvani, A., 576 Yokouchi, Y., 72
Subject Index
Activated partial thromboplastin time, | Candida albicans, 72 Eosinophils, 111, 351
Acute lung injury, 657 Capsaicin, 309 Eotaxin, 351
Acute phase protein, 631 Carboxymehtyl- E-Selectin, 253
Adenocarcinoma, 4 cellulose, 164 Etidronate, 45
Adenosine, 171 Cartilage, 396, 405, 534 Experimental uveitis, 262
Adjuvant-induced arthritis, 45 damage, 396, 534 Eye, 373
ADP, 679 Cathelicidin, 609
Adrenoceptor agonists, 93 CD4+T cells, 87 Factor Beta 1, 53, 60
Aggregation, 679 CD44, 556 FCNC, 601
Air-pouch, 556 CD8+T cells, 87 Fibrinogen, 631
Airway epithelium, 230 Cell Fibronectin, 405
hyperrespon- culture, 663 Fibronectin fragment, 396, 405, 534
siveness, 636 inflammation, 636 migration, 125 FK506, 469, 544
Airways obstruction, 230 Cell-mediated immunity, 189
Alendronate, 45 Cellulose acetate, 277 Gastric ulcer, 484
Amines, 284 Central nervous system, 338 Gene profiling, 424
Anaphylaxis, 164 Cerebral ischemia, 497 Genome-wide analyses, 517
Androstenediol, 189 Chemokines, 4, 257, 576, 585 Glucocorticoid, 125, 262
Angiogenesis, 133, 576 Chemotactic factor, 623 Glucosamine, 679
Annexin 1, 125 Chondrocyte, 344, 377 GM-CSF, 13, 31
Anthistamines, 373 Chronic non-polypous rhinosinusitis, 111 Granulocyte and monocyte adsorptive
Antibacterial peptide, 609 Cimetidine, 181 apheresis, 277
Antigen-induced arthritis, 189 Clinic modeling randomized trial Granulocyte-
Antimicrobial peptides, 230 (CMRT), 696 colony stimulating factor (G-CSF), 696
Antisense oligonucleotides, 143 Clinical trials, 497 GroEL, 551
Aorta, 215, 390 CMC, 601
APACHE, 158 Cockroach extract, 489 Haematological parameters, 442
Apoptosis, 125, 344, 609 Colitis, 329, 458, 462 Haemorrhagic hypotension, 316
Arachidonic acid, 66, 657 Collagen-induced arthritis, 469, 669 Haemorrhagic shock, 269
Arginine vasopressin, 269 Compound 48/80, 453 Haplotype, 484
Asthma, 78, 171, 636 Conditioned Media, 567 Heat shock proteins, 551
Astrocytes, 245 Controlled- Hemorrhage, 13
Atherosclerosis, 523 release preparations, 363 Heparin, |
Atherosclerotic plaque, 631 Coronary arteritis, 72 HGF, 277
ATP, 118 Coronary artery endothelial cells, 253 High dilutions, 181
Autoantibodies, 189 COS-2, 217 High risk, 164
Axon-reflex, 309 Crohn's disease, 551 Histaminase, 324
CRP, 631 Histamine, 38, 87, 181, 245, 269
B. lanceolatus venom, 284 Cyclic-AMP, 31 H1-receptor, 245
Bacteremia, 292 Cyclooxygenase (COX), 297, 688 H2 receptor, 223, 245
Basophils, 171, 181, 211 COX-1, 217 H3-receptor, 245
BEAS-2B, 31 Cyclosphosphamide, 205 H4-receptor, 245
Beta2-integrins, 523 Cytokines, 93, 523, 663, 669 liberation, 211
Bioassay, 53, 60, 205 receptor, 87
Biocompatible materials, 363 Damage, 405 receptor knock-out mice, 324
Bisphospho- Dehydroepiandrosterone, 189 release, 164
nate(s), 45 Dendritic cells, 424 Histaminergic system, 316
Bone cell damage, 669 Dexamethasone, 217 Histidine, 181
Borrelia burgdorferi, 688 Diabetes mellitus, 22 Histidine decarboxylase, 215, 390
BQ-485, 329 Differential expression, 223 Histoplasma capsulatum, 351
BQ788, 329 Dithiocarbamate, 22 HNE, 601
Bradykinin, 78, 284 Drotrecogin alfa (activated), 528 hsp60, 551
BI receptors, 652 Dual 5-LOX/COX inhibition, 150 hsp65, 551
receptor antagonist, 78 Human, 215, 424
Brain injury, 338 E. coli, 551 dendritic cells, 413
Bronchial smooth muscle, 636 Elevated plus-maze, 696 dental pulp cells, 199
Budesonide, 663 ELISA, 60, 164 mast cell line, 663
Endarterectomy, 631 pathogens, 413
CS5a receptor, 623 Endothelins, 329 HUVEC, 567
Calcitonin gene-related peptide, 652 Endothelium, 585 Hyaluronan, 396, 534
Calcium, 304 Endotoxemia, 93 Hyaluronic acid, 396, 534, 556
Camptothecin, 355 Endotoxin, 13 films, 355

Hyperalgesia, 297, 652 Matrix metalloproteinase (MMP), 377, Rheumatoid arthritis, 217, 469, 544
Hypersensitivity, 373 462, 669
Hypoxia, 344 MDA, 601 S19 ribosomal protein, 623
Metalloproteinase, 284, 556, 688 SAPS, 158
IBD, 329, 551 Methotrexate, 544 Secretagogues, 453
ICAM-1, 143, 458 Metoprine, 316 Sepsis, 205, 528, 696
Immune complexes, 78 Microcirculation, 442 Serotonin, 66
Immuno-suppression, 13 Microdialysis, 118 Severe sepsis, 158
In vitro assays, 150 Microspheres, 363 Sickness behavior, 696
In vivo arthritis models, 133 MIP-lalpha, 351 Single nucleotide polymorphism, 484
Indomethacin, 262 Monocytes, 100, 304, 623 Smooth muscle, 390
Inducible nitric oxide synthase, 22, 262 Mononuclear cells, 528 Social interaction, 696
Infections, 413 Mother tinctures, 150 Sodium Dodecyl Sulphate SDS, 118
Inflammatory acute phase proteins, 517 mRNA, 215 Spinal cord, 297
Inflammatory cytokine, 462, 544 Myocardial ischemia, 585 Spleen cells, 669
Innate Immunity , 475, 567 Squamous metaplasia, 230
Integrins, 458 Nasal polyposis, 111 Stroke, 497
Intensive care, 338 Neuroblastoma, 297 Substance P, 652
Interleukin | (IL-1), 53, 60 Neuropeptides, 199 Surgical adhesions, 355
alpha, 217 Neutropenia, 205 Surgical flaps, 1
beta, 199, 377, 469 Neutrophil migration, 143 Synovial inflammation, 66
receptor antagonist, 53, 60 Neutrophils, 1, 111, 257, 292, 351, 657 Systemic vasculitis, 72
Interleukin-2, 234 NF-kappaB, 22, 253, 257, 528
Interleukin-6, 199, 205, 253, 469 NGF, 245 T lymphocyte proliferation, 324
Interleukin-10, 338 Nicotine, 211 T7 cell line, 475
Interleukins, 158 Nitric oxide, 22, 344, 373, 442, 475, Thl/Th2 balance, 189
Intestinal inflammation, 329 652 Thermal hyperalgesia, 309
Intra-articular injections, 363 NO, 405 Thrombosis, 679
Intracellular calcium, 489 Non-cholinergic receptor, 211 TNBS, 329
Intracellular cytokines, 100 Noradrenaline, 309 Transforming growth, 53, 60
Intravenous immunoglobulin, 253 Transwell, 475
Ischemia, 329 Open field, 696 Treatment efficacy, 363
Osteoarthritis, 396, 534 Tumor necrosis factor-alpha, 13, 199,
Kawasaki Disease, 72 Oxidative stress, 601 205, 292, 377, 469
Ketamine, 304 Type | diabetes, 652
KF19514, 31 Paclitaxel, 363
Kinins, 652 Pain, 118, 297 Ulcerative colitis, 53, 551
Knockout mice, 87 PAR-2 deficient mice, 489
Pathogen host interaction, 688 Vascular permeability, 284
Lactoferrin, 292 Pattern recognition receptors, 100
Leflunomide, 544 PDE4 inhibitor, 31 Western blot, 297
Leishmania major, 38 Peripheral blood mononuclear cells, 4
Leucocyte Beta2 integrin, 277 pH, 118 Zafirlukast, 373
Leukocyte, 1, 205, 585 Phospholipase A2, 284 Zeel comp. N, 150
aggregation, 458 Platelet, 679
influx, 576 recruitment, 523 Polyclonal antibodies, 223
endothelial interactions, 442 Primary cells, 223
Leukotriene receptor antagonist, 66 Procalcitonin, 158
L-histidine decarboxylase, 38 Proliferation, 230
Lipopolysaccharide, 107, 262, 304, 609, Prostaglandin E2, 118, 657
657 Proteoglycan, 396, 534
5-Lipoxygenase inhibitor, 66 PTK787/ZK222584, 133
Liver-failure, 93
Local Shwartzman Reaction, 107 Quality of life, 696
LPS-activated macrophage inflammato-
ry products, 567 R(-)alpha-methylhistamine, 316
Lung, 4 Ranitidine, 181
Lung fibroblast, 489 Rat, 269, 316, 390
Lung inflammation, 78 cardiac mast cells, 453
puw edema, 284
Macrophages, 4, 324 Repair, 405
Mast cells, 38, 107, 171, 309 thAPC, 528